The proposed sale forms part of a strategic shift to strengthen the group’s balance sheet and concentrate on priority growth areas.
In a statement issued on December 29, Aspen confirmed that its wholly owned subsidiary, Aspen Global Incorporated, has entered into binding agreements to sell 100% of its Asia-Pacific business to Australian private investment firm BGH Capital. The deal covers operations and intellectual property in Australia, New Zealand, Hong Kong, Malaysia, Taiwan and the Philippines.
The business being sold has been a major contributor to Aspen’s international expansion, accounting for 18% of group revenue and 26% of group earnings before interest, tax, depreciation and amortisation in the financial year ended June 30. Aspen said the offer was unsolicited, but its Board concluded that it represented compelling value for shareholders after careful evaluation.
The transaction implies an enterprise value multiple of about 11 times normalised earnings and will be completed on a cash and debt-free basis, subject to standard adjustments. Aspen plans to use the bulk of the proceeds to reduce group debt, lower financing costs and simplify its lender base, improving flexibility for future investment.
Completion of the sale is expected to allow Aspen to focus more sharply on its strategic growth drivers. These include expanding its commercial pharmaceuticals business in emerging markets, scaling up production of diabetes and weight-loss treatments, and restoring profitability at loss-making sterile manufacturing facilities in SA and France by 2027.
Aspen said the Asia-Pacific operations are well-established and sufficiently standalone to allow for a smooth separation. BGH Capital, which manages more than $4.15 billion in committed funds, has a strong focus on healthcare investments in Australia and New Zealand.
The proposed disposal is classified as a Category 1 transaction under JSE Listings Requirements and will require shareholder approval at a general meeting. Aspen expects the transaction to be completed in the second quarter of the 2026 calendar year, subject to regulatory clearances.
–ChannelAfrica–
